Cuur Health

ALERT
When outdoor temperatures reach 1050 our mobile COVID-19 testing site closes for the day to ensure the safety of our medical staff. Thank you for your understanding.
Cuando las temperaturas exteriores alcanzan los 105 grados Nuestra prueba de COVID-19 móvil está cerrada durante el día para garantizar la seguridad de nuestro personal médico. Gracias por su comprensión.

Vaginal Microbiota Panel

VAGINAL MICROBIOTA PANEL

CUUR HEALTH is dedicated to maintaining the largest data set of infectious disease targets available in the world.

The implications of diagnosing women’s health infections extend far beyond that of each patient – it can affect their partners and even their children. Particularly when it comes to infectious disease, it’s essential to get fast, reliable and actionable results.

The newly discovered female urinary microbiota has the potential to deepen our understanding of urinary tract health and disease, including common lower urinary tract conditions such as urinary incontinence and urinary tract infection. The female urinary microbiota possesses characteristics that differ between women affected by urgency urinary incontinence and matched, unaffected controls.

Traditional culture-based or microscopy-based methods for analysis of the vaginal microbiota can be time-consuming, overly subjective and inaccurate due to lack of sensitivity and specificity. CUUR HALTH’S molecular technology solution can detect microbes that are slow growing, difficult to grow or that fail to grow under traditional methods providing clear, precise and actionable categorization of microorganisms involved.

Helix DNA
TARGETS
[table “” not found /]

Infectious Disease Care
STATISTICALLY SPEAKING
  • Vulvovaginal candidiasis (VVC) affects about 75% of reproductive-aged women at least once during their lives, with about 5% of them suffering of recurrences.
  • Chlamydia trachomatis (CT) represents the most common bacterial STI worldwide, and new infections probably exceed 131 million per year